Sign in
CompletedPhase 2

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

Key facts

Who runs it
Regeneron Pharmaceuticals
Where
Atlanta, Baltimore, Boston, Brooklyn, Charleston, Cleveland, Murray, Nashville, New Haven, New York, The Bronx, Tucson, and Winston-Salem, United StatesSee the 16 sitesAlso in 1 other country, 13 sites
Status
Completed
Phase
Phase 2
People taking part
76 people enrolled
Started
5 May 2025
Ended
28 Apr 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • REGN7544
  • PB
Record updated
20 May 2026

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Proven or suspected infection defined as administration or planned administration of antimicrobial therapy within the screening period
  • Sepsis-induced hypotension that has not responded to Intravenous (IV) fluids, receiving 1 or 2 vasopressors and maintaining a Mean Arterial Pressure (MAP) of ≥ 65 mm Hg for at least 2 consecutive hours immediately prior to randomization, as defined in the protocol

Who cannot take part

  • Any prior diagnosis of severe pulmonary hypertension, as defined in the protocol
  • Receiving 3 or more vasopressors or exceeding the maximal combined dose as defined in the protocol, during the screening period or at the time of study drug administration
  • Received bone marrow transplant during the preceding 6 months or chemotherapy during the preceding 30 days for lymphoma or leukemia; NOTE: Other Protocol-Defined Inclusion-Exclusion Criteria Apply
  • Primary cause of hypotension suspected to be due to non-sepsis cause (eg, hemorrhage, burns, or cardiogenic shock), including shock after cardiac arrest
  • Acute coronary syndrome based on clinical symptoms and/or electrocardiogram (ECG) during hospitalization
  • History of hospitalization due to heart failure, myocardial infarction, stroke, clinically significant ventricular arrhythmia, transient ischemic attack, or unstable angina within the preceding 3 months
  • Ejection fraction <20% in the most recent known echocardiogram
  • Unable to obtain informed consent by participant or Legally Authorized Representative (LAR)
  • Clinical status requires vasopressor and/or Blood Pressure (BP) management inconsistent with the study protocol

Where in United States

Also in 1 other country, 13 sites

  • Emory University HospitalAtlanta, United States
  • Johns Hopkins HospitalBaltimore, United States
  • Harvard Medical School Beth Israel Deaconess Medical CenterBoston, United States
  • Massachusetts General HospitalBoston, United States
  • New York University Langone Health Brooklyn HospitalBrooklyn, United States
  • MUSC SCTR Research Nexus Clinic and LabCharleston, United States
  • Cleveland Clinic FoundationCleveland, United States
  • Intermountain Medical Center - Murray (Pulmonary Medicine)Murray, United States
  • Vanderbilt University Medical CenterNashville, United States
  • Yale UniversityNew Haven, United States
  • Bellevue HospitalNew York, United States
  • New York University Langone Health Tisch-Kimmel HospitalNew York, United States
  • Montefiore Medical Center - Moses CampusThe Bronx, United States
  • Montefiore Medical Center-Weiler HospitalThe Bronx, United States
  • University of ArizonaTucson, United States
  • Atrium HealthWinston-Salem, United States

About the trial

What the trial wants to find out

This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis.

Read full original descriptionShow less

The aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during the stay in the hospital.

The study is looking at several other research questions, including:

* How the study drug changes the blood pressure and the amount of intravenous (IV) fluids given to participants with low blood pressure due to sepsis * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

The 2 groups in the trial

  • REGN7544Treatment being tested
  • Placebo (PB)Placebo, for comparison

    Treatment: PB

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN7544, an Antagonist Monoclonal Antibody to NPR1, in Patients With Sepsis-Induced Hypotension
Record updated
20 May 2026